ArticleNeuroscience applied2023
The BrainDrugs-epilepsy study: A prospective open-label cohort precision medicine study in epilepsy.
Article in Neuroscience applied, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05450822 (The BrainDrugs-Epilepsy Study), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy
Who cites it
2 citing papers in PubMed.
- Assessment of cerebral drug occupancy in humans using a single PET-scan: A [European journal of nuclear medicine and molecular imaging · 2024Observational
- Deep phenotyping towards precision psychiatry of first-episode depression - the Brain Drugs-Depression cohort.BMC psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The BrainDrugs-Epilepsy Study is part of the established Lundbeck Foundation funded BrainDrugs research alliance (braindrugs.nru.dk). The study aims to identify biomarkers of treatment outcome as well as cognitive and psychiatric comorbidity in patients with a first epileptic seizure and epilepsy. Our goal is to provide a patient-level prediction of treatment response. Methods: In a prospective cohort study design, we will consecutively include a total of 200 patients who have experienced their first epileptic seizure and 150 newly diagnosed patients with epilepsy ( Discussion: We hypothesize that seizures, cognitive impairment, and psychiatric symptoms share common neurobiological mechanisms that can be identified using MRI, PET, and EEG. We will assess how these biomarkers change over time and in response to treatment, providing novel insights into disease trajectories in the first years of epilepsy. Clinical trial registration: NCT05450822. Retrospectively registered July 5, 2022 (https://clinicaltrials.gov/ct2/results?term=NCT05450822&Search=Search).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.